Navigation Links
Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
Date:9/3/2009

SUNNYVALE, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that Dr. Glenn Rice, President and COO, will provide a business overview at the following conferences:

-- Thomas Weisel Partners 2009 Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 9th at 3:50 p.m. EDT.

-- Rodman & Renshaw 11th Annual Healthcare Conference at the Palace Hotel in New York on Thursday, September 10th at 12:05 p.m. EDT.

There will be a live webcast of the presentations, which will be accessible through a link posted on the investor relations / events & webcasts section of the PCYC website, please go to http://ir.pharmacyclics.com/events.cfm. The webcasts will be available for replay through October 10th, 2009.

About Pharmacyclics

Pharmacyclics((R)) is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in c
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmacyclics, Inc. Rights Offering Oversubscribed
2. Pharmacyclics Announces Subscription Price for Rights Offering
3. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
4. Pharmacyclics Files Registration Statement for Rights Offering
5. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
6. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
7. Pharmacyclics Secures $5.0 Million in Debt Financing
8. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
9. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
10. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
11. Pharmacyclics Announces It Received Nasdaq Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 2014 Ontotext S4 , The ... Ontotext . Now the same enterprise hardened text ... and unstructured data is available to start-ups and mid-size ... technology. Organizations that do not have resources to evaluate ... use S4 since there is no need for on ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4RENU 28 Skin Care Now Available in Australia and New Zealand 2
... Inc., a,privately-held, development-stage pharmaceutical company dedicated to treating,diseases ... defenses, today,announced that the National Institutes of Health ... excess of $850,000. , ... to advance the development of safe and,effective medical ...
... InSightec Ltd.,announced today that cancer patients suffering pain ... have a new online resource for information about,their ... bone metastases, as well as detailed information about ... the U.S., Canada and,Israel to evaluate whether treatment ...
... Who Can Benefit from Vectibix(R) , ... Amgen (Nasdaq: AMGN ) today announced they ... gene as a predictive biomarker in patients with ... receptor (EGFr) antibody Vectibix(R) (panitumumab) with the U.S. Food ...
Cached Biology Technology:Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 2Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury 3MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases 2MyCancerPain.org Launched as Resource for Patients with Painful Bone Metastases 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... and salty aroma of sunscreen and seawater signals a ... reporting that the idyllic beach vacation comes with an ... and into the sea, they can become toxic to ... main course for many other marine animals. Their study ... Technology . , Antonio Tovar-Sanchez and David Snchez-Quiles point ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
... improve its system for ensuring the safety of its ... Academy of Sciences say. Despite having 40% of the ... independent regulatory agency and sufficient staff to keep pace ... article in ACS,s journal Environmental Science & Technology. ...
... The obscure technology used in heated automobile seats, gadgets that ... devices is undergoing a renaissance and could well emerge as ... play other key roles in addressing some of society,s most ... the technology termed thermoelectrics in the current issue ...
... Elser, Argentina,s soaring, glacier-laden peaks, ancient cultures, and criollo ... draw: access to the "last unpolluted aquatic ecosystems on ... Elser and colleague Esteban Balseiro of the Universidad Nacional ... alpine lakes close to San Carlos de Barliloche in ...
Cached Biology News:Fulbright scholar takes ecological theory to Andean heights 2Fulbright scholar takes ecological theory to Andean heights 3
... exciting new chapter to a ... Agilents 7890A GC gives you ... your lab to the next ... performance, including advanced separation capabilities, ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... CaspaTag™ Pan-Caspase In Situ Assay Kit is ... caspases in cells undergoing apoptosis. The kit ... use in diagnostic or therapeutic procedures. CHEMICON®s ... a novel approach to detect active caspases. ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
Biology Products: